Lin J - Search Results

1

Mycosis fungoides and sezary syndrome: an update.

Kim EJ, Lin J, Junkins-Hopkins JM, Vittorio CC, Rook AH. Kim EJ, et al. Among authors: lin j. Curr Oncol Rep. 2006 Sep;8(5):376-86. doi: 10.1007/s11912-006-0061-1. Curr Oncol Rep. 2006. PMID: 16901399 Review.

2

High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.

Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, Rook AH. Richardson SK, et al. Among authors: lin jh. Clin Lymphoma Myeloma. 2006 Nov;7(3):226-32. doi: 10.3816/CLM.2006.n.063. Clin Lymphoma Myeloma. 2006. PMID: 17229339 Clinical Trial.

3

IL-21 enhances antitumor responses without stimulating proliferation of malignant T cells of patients with Sézary syndrome.

Yoon JS, Newton SM, Wysocka M, Troxel AB, Hess SD, Richardson SK, Lin JH, Benoit BM, Kasprzycka M, Wasik MA, Rook AH. Yoon JS, et al. J Invest Dermatol. 2008 Feb;128(2):473-80. doi: 10.1038/sj.jid.5701027. Epub 2007 Aug 23. J Invest Dermatol. 2008. PMID: 17713571 Free article.

4

Clinical and in vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-alpha receptor.

Lin JH, Kim EJ, Bansal A, Seykora J, Richardson SK, Cha XY, Zafar S, Nasta S, Wysocka M, Benoit B, Rook AH, Fakharzadeh SS. Lin JH, et al. Blood. 2008 Sep 15;112(6):2484-8. doi: 10.1182/blood-2008-03-141424. Epub 2008 Jun 16. Blood. 2008. PMID: 18559673 Free PMC article.

5

Bexarotene blunts malignant T-cell chemotaxis in Sezary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine.

Richardson SK, Newton SB, Bach TL, Budgin JB, Benoit BM, Lin JH, Yoon JS, Wysocka M, Abrams CS, Rook AH. Richardson SK, et al. Am J Hematol. 2007 Sep;82(9):792-7. doi: 10.1002/ajh.20952. Am J Hematol. 2007. PMID: 17546636 Free article.

6

Reliability and convergent validity of two outcome instruments for pemphigus.

Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, Pandya AG, Payne AS, Rose M, Rubenstein D, Woodley D, Vittorio C, Werth BB, Williams EA, Taylor L, Troxel AB, Werth VP. Rosenbach M, et al. Among authors: lin j. J Invest Dermatol. 2009 Oct;129(10):2404-10. doi: 10.1038/jid.2009.72. Epub 2009 Apr 9. J Invest Dermatol. 2009. PMID: 19357707 Free PMC article.

7

Pathophysiology of cutaneous lupus erythematosus.

Lin JH, Dutz JP, Sontheimer RD, Werth VP. Lin JH, et al. Clin Rev Allergy Immunol. 2007 Oct;33(1-2):85-106. doi: 10.1007/s12016-007-0031-x. Clin Rev Allergy Immunol. 2007. PMID: 18094949 Review.

8

Ultraviolet-B recruits mannose-binding lectin into skin from non-cutaneous sources.

Lokitz ML, Zhang W, Bashir M, Sullivan KE, Ang G, Kwon EJ, Lin JH, Werth VP. Lokitz ML, et al. J Invest Dermatol. 2005 Jul;125(1):166-73. doi: 10.1111/j.0022-202X.2005.23794.x. J Invest Dermatol. 2005. PMID: 15982317 Free PMC article.

9

A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.

Corey K, Cook D, Bekker J, Mugnaini E, Lin JH. Corey K, et al. Among authors: lin jh. JAMA Dermatol. 2014 Feb;150(2):210-2. doi: 10.1001/jamadermatol.2013.5741. JAMA Dermatol. 2014. PMID: 24352253 No abstract available.

10

Enhanced therapeutic potential of Flotillins-modified MenSCs by improve the survival, proliferation and migration.

Cheng F, Ji L, Li P, Han Z, He Y, Yang F, Xu Z, Li Y, Ruan T, Zhu X, Lin J. Cheng F, et al. Among authors: lin j. Mol Biol Rep. 2024 May 25;51(1):680. doi: 10.1007/s11033-024-09624-0. Mol Biol Rep. 2024. PMID: 38796595

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

38,593 results

Search Page